Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.53 |
| ▸ | PGR | P06401 | 3/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279436 | 0.99 | NR3C1 (0.52) | NR3C1PGRNR3C2 | |
| SCHEMBL4740189 | 0.84 | NR3C1 (0.57) | NR3C1PGRNR3C2 | |
| SCHEMBL6692378 | 0.80 | NR3C1 (0.50) | NR3C1PGRNR3C2 | |
| SCHEMBL6554510 | 0.78 | NR3C1 (0.52) | NR3C1PGRNR3C2 | |
| SCHEMBL4163146 | 0.75 | NR3C1 (0.53) | NR3C1PGRNR3C2 | |
| SCHEMBL4278672 | 0.74 | NR3C1 (0.52) | NR3C1PGRNR3C2 | |
| SCHEMBL4176230 | 0.74 | NR3C1 (0.46) | NR3C1PGRNR3C2 | |
| SCHEMBL6689551 | 0.74 | NR3C1 (0.52) | NR3C1PGRNR3C2 | |
| SCHEMBL4173498 | 0.74 | NR3C1 (0.49) | NR3C1PGRNR3C2 | |
| SCHEMBL4167078 | 0.74 | NR3C1 (0.47) | NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2009-10-29 | — | — | US | disclosed |
| WO-2009077186-A1 | NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESLLSCHAFT (DE) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077186-A1 | NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESLLSCHAFT (DE) | 2009-06-25 | — | — | WO | disclosed |
| EP-2070909-A1 | Non-steroidal progesterone receptor modulators | Bayer Schering Pharma AG (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2070909-A1 | Non-steroidal progesterone receptor modulators | Bayer Schering Pharma AG (DE) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | NR3C1 61/4885PGR 1/4885NR3C2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.